{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:58:41Z","timestamp":1768586321552,"version":"3.49.0"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 60-year-old man diagnosed with gastric adenocarcinoma underwent FDG PET\/CT. After completing 9 cycles of combination chemotherapy with nivolumab and FOLFOX, he had multiple new nodular uptakes in the bilateral cervical chains and mediastinum. The pathology of the right neck node confirmed reactive lymph node hyperplasia without evidence of malignancy, suggesting pseudoprogression after immunotherapy. It is worthwhile to report these PET image patterns, as they could significantly influence clinical decision-making.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005515","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T19:00:32Z","timestamp":1730487632000},"page":"1139-1141","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["FDG PET Images of Pseudoprogression After Nivolumab-FOLFOX Chemotherapy in a Gastric Cancer Patient"],"prefix":"10.1097","volume":"49","author":[{"given":"Yeongjoo","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Sung","family":"Won","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Jin","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Hospital Pathology, Uijeongbu St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae Jung","family":"Na","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Radiology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"57889","DOI":"10.18632\/oncotarget.18361","article-title":"Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/2326-6066.CIR-15-0197","article-title":"Radiologic heterogeneity in responses to anti-PD-1\/PD-L1 therapy in metastatic renal cell carcinoma","volume":"4","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases","volume":"58","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","volume":"34","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:07:17Z","timestamp":1750532837000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":7,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005515","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}